1 Mayuri Shetty, 1 George H. Neubauer, 1 Kathryn E. Stephenson, 1 Jean Pierre S. Peron, 3 Paolo M. de A. Zanotto, 3 Johnathan Misamore, 4 Brad Finneyfrock, 4 Mark G. Lewis, 4 Galit Alter, 5 Kayvon Modjarrad, 2, 6 Richard G. Jarman, 2 Kenneth H. Eckels, 2 Nelson L. Michael, 2 Stephen J. Thomas, 2 † Dan H. Barouch 1,5 † ‡ Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly.The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge.These data support the rapid clinical development of ZIKV vaccines for humans.
T he explosive and unprecedented ZIKV outbreak in the Americas (1, 2) prompted the World Health Organization to declare this epidemic a public health emergency of international concern. ZIKV has been causally associated with fetal microcephaly, intrauterine growth retardation, and other congenital malformations in both humans (3-6) and mice (7) (8) (9) , and it has also been linked with neurologic disorders such as Guillain-Barre syndrome (10) . Several reports have shown that ZIKV can infect placental and fetal tissues, leading to prolonged viremia in pregnant women (11) and nonhuman primates (12) . ZIKV also appears to target cortical neural progenitor cells (7-9, 13, 14) , which likely contributes to neuropathology.
We recently reported the protective efficacy of two vaccines against ZIKV challenges in mice: a purified inactivated virus (PIV) vaccine from ZIKV strain PRVABC59 and a DNA vaccine expressing an optimized premembrane and envelope (prM-Env) immunogen from ZIKV strain BeH815744 (15) . These studies used ZIKV challenge strains from Brazil (ZIKV-BR; Brazil/ZKV2015) (9) and Puerto Rico (ZIKV-PR; PRVABC59). ZIKV replication in mice was dependent on the mouse strain (15) and may be less extensive than in nonhuman primates (12) . We therefore evaluated the immunogenicity and protective efficacy of inactivated virus, DNAbased, and vector-based vaccines against ZIKV challenge in rhesus monkeys.
ZIKV PIV vaccine study
We first immunized 16 rhesus monkeys by the subcutaneous route with 5 mg of ZIKV PIV vaccine plus alum (n = 8) or sham vaccine (alum only) (n = 8) at weeks 0 and 4 ( fig. S1 ). All PIV-vaccinated animals developed ZIKV Env-specific binding antibodies, as measured by enzyme-linked immunosorbent assays (ELISAs), and ZIKV-specific neutralizing antibodies, as measured by microneutralization (MN50) assays, at week 2 after initial immunization. Median log antibody titers at week 2 were 1.87 (Fig. 1A ) and 2.27 ( Fig. 1B) in ELISAs and MN50 assays, respectively. After the week 4 boost immunization, median log antibody titers increased substantially to 3.54 (Fig. 1A ) and 3.66 (Fig. 1B) , respectively, at week 6. In contrast, sham control monkeys did not develop detectable ZIKV-specific antibody responses ( fig. S2 ).
Binding antibody titers correlated with neutralizing antibody titers in the PIV-vaccinated animals (P < 0.0001, coefficient of correlation R = 0.88, Spearman rank correlation test; fig. S3 ). Only minimal antibody-dependent cellular phagocytosis responses were observed. The majority of PIV-vaccinated monkeys ( To assess the protective efficacy of the PIV vaccine against ZIKV challenge, we infected PIVimmunized and sham control monkeys by the subcutaneous route with 10 6 viral particles [vp; 10 3 plaque-forming units (PFU)] of ZIKV-BR or ZIKV-PR (n= 4 per group) (15) . Viral loads after ZIKV challenge were quantitated by reverse transcription polymerase chain reaction (15) , and viral infectivity was confirmed by growth in Vero cells. ZIKV-specific MN50 titers increased after challenge, particularly in the sham controls ( fig. S5 ). Sham control monkeys exhibited 6 to 7 days of detectable viremia, with median peak viral loads of 5.82 log copies/ml (range, 5.21 to 6.29 log copies/ml; n = 8) on day 3 to 5 after challenge ( Fig. 2A) . Virus was also detected in the majority of sham control animals in urine and cerebrospinal fluid (CSF) on day 3, as well as in colorectal secretions and cervicovaginal secretions on day 7 (Fig. 2 , B to E). In contrast, PIV-vaccinated monkeys showed complete protection against ZIKV challenge, as evidenced by no detectable virus (<100 copies/ml) in the blood, urine, CSF, colorectal secretions, or cervicovaginal secretions in any animal after challenge (n = 8; P = 0.0002, Fisher's exact test comparing PIV-vaccinated animals with sham controls). We were unable to assess ZIKV in semen in the male animals in this study because of inadequate sample volumes. No major differences in plasma viral loads were observed between the sham controls that received ZIKV-BR versus those that received ZIKV-PR ( fig. S6 ).
Adoptive transfer studies
We next explored the mechanism of the observed protection through adoptive transfer studies.
Using protein G affinity chromatography, we purified immunoglobulin G (IgG) from plasma from PIV-vaccinated monkeys at week 8. Vaccineelicited, ZIKV-specific IgG was then infused into four groups of naïve Balb/c mice (n = 5 per group) as fivefold serial dilutions of the purified IgG preparation, which had a log ELISA titer of 3.30 and a log MN50 titer of 3.30. After infusion, these groups of recipient mice (designated I, II, III, and IV) had median log ELISA titers of 2.83, 2.35, 1.40, and <1.00 (Fig. 3A) and median log MN50 titers of 2.93, 1.77, 1.14, and <1.00 (Fig. 3B ), respectively. Mice were then challenged by the intravenous route with 10 5 vp (10 2 PFU) of ZIKV-BR, as we have previously described (15) . The higher two doses of purified IgG provided complete protection after ZIKV challenge, whereas the lower two doses of purified IgG resulted in reduced viremia compared with sham-infused control mice (Fig. 3, C to E) .
Vaccine-elicited, ZIKV-specific IgG was also infused into two groups of naïve rhesus monkeys (n = 2 per group). After infusion, these groups of recipient monkeys (designated I and II) had respective median log MN50 titers of 2.11 and 1.22 (Fig. 4A ). Monkeys were then challenged with 10 6 vp (10 3 PFU) of ZIKV-BR. In the animals that received the higher IgG dose, one animal was completely protected and the other showed a blip of viremia on days 3 to 5 (Fig. 4B) . No enhancement of viral replication was observed at subtherapeutic IgG concentrations. Taken together, these data demonstrate that purified IgG from PIV-vaccinated rhesus monkeys provided passive protection against ZIKV challenge after adoptive transfer to both rodents and primates.
ZIKV DNA and adenovirus vaccine study
To evaluate the immunogenicity and protective efficacy of DNA-and vector-based ZIKV vaccines, we immunized 12 rhesus monkeys with a plasmid DNA vaccine (15) or a rhesus adenovirus serotype 52 (RhAd52) vector-based vaccine (16) (fig. S1 ). Monkeys were immunized by the intramuscular route with 5 mg of DNA vaccine expressing prM-Env at weeks 0 and 4 (n = 4), with 10 11 vp of RhAd52 vector expressing prM-Env as a single immunization at week 0 (n = 4), or with sham vaccine at weeks 0 and 4 (n = 4). The DNAprM-Env vaccine induced ZIKV-specific neutralizing antibody titers in all animals after the week 4 boost immunization, although only minimal MN50 titers were detected after the initial priming immunization (Fig. 5A) . In contrast, the RhAd52-prM-Env vaccine induced ZIKV-specific neutralizing antibody responses in all animals at week 2 after the initial priming immunization (Fig. 5A) . Moreover, the RhAd52-prM-Env vaccine induced a substantial breadth of antibody responses against linear ZIKV Env epitopes, as measured by peptide (Fig. 6 ).
Discussion
We demonstrate that three different vaccine platforms provide complete protection against ZIKV challenge in rhesus monkeys. No specific clinical safety adverse effects related to the vaccines were observed. We recently reported the protective efficacy of the PIV vaccine and the DNA-prM-Env vaccine in mice (15) . The present data confirm and extend these prior studies by demonstrating robust protection against ZIKV challenge in nonhuman primates and specifically using the vaccination doses, routes, and schedules that are typically evaluated in clinical trials. Although the PIV vaccine and the DNA-prM-Env vaccine appeared comparably immunogenic in mice (15) , the former proved more potent in rhesus monkeys under the conditions tested (Figs. 1 and  5 ). To generalize these observations to a vectorbased vaccine, we also evaluated the RhAd52-prMEnv vaccine, which proved highly immunogenic and afforded complete protection after a single immunization in monkeys (Fig. 5) . Rhesus adenovirus vectors have the potential advantage of minimal baseline vector-specific neutralizing antibodies in human populations (16) .
The adoptive transfer studies demonstrate that vaccine-elicited antibodies are sufficient for protection against ZIKV challenge. Moreover, passive protection in mice and rhesus monkeys was observed at relatively low antibody titers (Figs. 3 and 4) . Such antibody titers are likely achievable in humans with these vaccine platforms, thus raising optimism for the development of a ZIKV vaccine for humans. Future preclinical and clinical studies will need to address the potential impact of cross-reactive antibodies against dengue virus and other flaviviruses. Secondary infection with a heterologous dengue serotype can be clinically more severe than initial infection, which may or may not reflect antibody-dependent enhancement (18, 19) . Cross-reactive antibodies for ZIKV and dengue virus have also been described (20, 21) , and dengue-specific antibodies have been reported to increase ZIKV replication in vitro (22) . The relevance and implications of these findings for ZIKV vaccine development remain to be determined.
The consistent and robust antibody-based correlates of vaccine protection against ZIKV challenge in both rodents and primates suggest the generalizability of these findings. Similar correlates of protection, and specifically neutralizing antibody titers >10, have been reported for other flavivirus vaccines in humans (23) (24) (25) . Together, these data suggest a path forward for clinical development of ZIKV vaccines in humans. PIV vaccines have been evaluated previously in clinical trials for other flaviviruses, including dengue virus, tick-borne encephalitis virus, and Japanese encephalitis virus (26) (27) (28) (29) (30) 
